Literature DB >> 26551337

Molecular Dynamics Simulations and Structural Analysis of Giardia duodenalis 14-3-3 Protein-Protein Interactions.

Ylenia Cau1, Annarita Fiorillo2, Mattia Mori1,3, Andrea Ilari4, Maurizo Botta1,5, Marco Lalle6.   

Abstract

Giardiasis is a gastrointestinal diarrheal illness caused by the protozoan parasite Giardia duodenalis, which affects annually over 200 million people worldwide. The limited antigiardial drug arsenal and the emergence of clinical cases refractory to standard treatments dictate the need for new chemotherapeutics. The 14-3-3 family of regulatory proteins, extensively involved in protein-protein interactions (PPIs) with pSer/pThr clients, represents a highly promising target. Despite homology with human counterparts, the single 14-3-3 of G. duodenalis (g14-3-3) is characterized by a constitutive phosphorylation in a region critical for target binding, thus affecting the function and the conformation of g14-3-3/clients interaction. However, to approach the design of specific small molecule modulators of g14-3-3 PPIs, structural elucidations are required. Here, we present a detailed computational and crystallographic study exploring the implications of g14-3-3 phosphorylation on protein structure and target binding. Self-Guided Langevin Dynamics and classical molecular dynamics simulations show that phosphorylation affects locally and globally g14-3-3 conformation, inducing a structural rearrangement more suitable for target binding. Profitable features for g14-3-3/clients interaction were highlighted using a hydrophobicity-based descriptor to characterize g14-3-3 client peptides. Finally, the X-ray structure of g14-3-3 in complex with a mode-1 prototype phosphopeptide was solved and combined with structure-based simulations to identify molecular features relevant for clients binding to g14-3-3. The data presented herein provide a further and structural understanding of g14-3-3 features and set the basis for drug design studies.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26551337     DOI: 10.1021/acs.jcim.5b00452

Source DB:  PubMed          Journal:  J Chem Inf Model        ISSN: 1549-9596            Impact factor:   4.956


  5 in total

Review 1.  An overview of recent molecular dynamics applications as medicinal chemistry tools for the undruggable site challenge.

Authors:  Ugo Perricone; Maria Rita Gulotta; Jessica Lombino; Barbara Parrino; Stella Cascioferro; Patrizia Diana; Girolamo Cirrincione; Alessandro Padova
Journal:  Medchemcomm       Date:  2018-04-19       Impact factor: 3.597

2.  In vivo crystals reveal critical features of the interaction between cystic fibrosis transmembrane conductance regulator (CFTR) and the PDZ2 domain of Na+/H+ exchange cofactor NHERF1.

Authors:  Eleanor R Martin; Alessandro Barbieri; Robert C Ford; Robert C Robinson
Journal:  J Biol Chem       Date:  2020-02-02       Impact factor: 5.157

Review 3.  Modulators of 14-3-3 Protein-Protein Interactions.

Authors:  Loes M Stevers; Eline Sijbesma; Maurizio Botta; Carol MacKintosh; Tomas Obsil; Isabelle Landrieu; Ylenia Cau; Andrew J Wilson; Anna Karawajczyk; Jan Eickhoff; Jeremy Davis; Michael Hann; Gavin O'Mahony; Richard G Doveston; Luc Brunsveld; Christian Ottmann
Journal:  J Med Chem       Date:  2017-10-19       Impact factor: 7.446

4.  Chemical, computational and functional insights into the chemical stability of the Hedgehog pathway inhibitor GANT61.

Authors:  Andrea Calcaterra; Valentina Iovine; Bruno Botta; Deborah Quaglio; Ilaria D'Acquarica; Alessia Ciogli; Antonia Iazzetti; Romina Alfonsi; Ludovica Lospinoso Severini; Paola Infante; Lucia Di Marcotullio; Mattia Mori; Francesca Ghirga
Journal:  J Enzyme Inhib Med Chem       Date:  2018-12       Impact factor: 5.051

5.  Chemically stable inhibitors of 14-3-3 protein-protein interactions derived from BV02.

Authors:  Leire Iralde-Lorente; Ylenia Cau; Letizia Clementi; Lorenzo Franci; Giusy Tassone; Daniela Valensin; Mattia Mori; Adriano Angelucci; Mario Chiariello; Maurizio Botta
Journal:  J Enzyme Inhib Med Chem       Date:  2019-12       Impact factor: 5.051

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.